N-(3-hydroxyphenyl)-Arachidonoyl amide
(Synonyms: 3-HPAA) 目录号 : GC15372
An irreversible COX-2 inhibitor
Cas No.:183718-75-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 2 μM
N-(3-hydroxyphenyl) -Arachidonoyl amide, also known as 3-HPAA, is an analog of AM404 (N-(4-hydroxyphenyl)-arachidonoyl amide), a selective inhibitor of carrier-mediated transport of arachidonoyl ethanolamide. 3-HPAA, metabolized by both cyclooxygenase (COX) -1 and COX-2, is an irreversible and selective inhibitor of COX-2 with an IC50 value of 2 M. 3-HPAA can be efficiently oxygenated to prostaglandin and hydroxyeicosatetraenoate products by prostaglandin endoperoxide synthase (PGHS) -2. It appears that 3-HPAA can be converted by PGHS-1 in a similar manner.
COX enzymes play elaborate roles in human physiology and pathology, involving neuronal, immune, renal, cardiovascular, gastrointestinal, and reproductive systems. COX enzymes are blocked by aspirin and a wide variety of other non-steroidal anti-inflammatory drugs, which makes them clinically important [1]. COX-2, overexpressed in cancer cells, promotes tumorigenesis and induces neo-angiogenesis. Additionally, it plays an important role in inflammation and pyrexia.
In vitro: Up to now, in vitro study of 3-HPAA is still in the development stage.
In vivo: Up to now, in vivo study of 3-HPAA is still in the development stage.
Reference:
[1]. Fitzpatrick, F. Cyclooxygenase Enzymes: Regulation and Function. Current Pharmaceutical Design. 2004; 10(6): 577-588.
| Cas No. | 183718-75-4 | SDF | |
| 别名 | 3-HPAA | ||
| 化学名 | N-(3-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide | ||
| Canonical SMILES | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Nc1cccc(O)c1 | ||
| 分子式 | C26H37NO2 | 分子量 | 395.6 |
| 溶解度 | ≤20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5278 mL | 12.639 mL | 25.2781 mL |
| 5 mM | 0.5056 mL | 2.5278 mL | 5.0556 mL |
| 10 mM | 0.2528 mL | 1.2639 mL | 2.5278 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet